目的 探讨表皮生长因子受体(EGFR)基因突变状态对晚期肺腺癌一线化疗疗效的影响.方法收集晚期肺腺癌且一线接受了以铂类为基础双药化疗患者的临床资料,分析EGFR基因状态与化疗疗效、无进展生存时间之间的关系.结果 一线接受含铂双药化疗的患者271例,EGFR 基因野生型患者192例(70.8%),EGFR基因敏感突变79例(29.2%).EGFR野生型和突变型一线化疗的客观有效率(RR)分别为30.2%和35.4%(P=0.524).疾病控制率(DCR)分别为71.9%和81.0%(P=0.292).EGFR突变型和野生型肺腺癌患者一线化疗的RR、DCR相比,差异无统计学意义.EGFR野生型中位无疾病进展生存时间(PFS)为4.6个月,EGFR突变型为5.3个月,两组数据差异无统计学意义(P=0.299).结论 晚期肺腺癌EGFR基因突变状态对一线化疗的近期疗效及无进展生存期无明显影响.%Objective To explore the impact of EGFR gene status to the therapeutic effect of first-line chemo-therapy in patients with advanced lung adenocarcinoma.Methods We had collected the clinical data of patients with advanced lung adenocarcinoma and treated with first-line combined chemotherapy based on platinum.We had analyzed the relationship of EGFR gene status with chemotherapeutic effect and progression free survival time.Results Of all the 271 patients who received first-line chemotherapy with platinum-based drugs,192 cases(70.8%)with wild EGFR gene,79 cases(29.2%)with mutation EGFR gene.The objective response rates of wild and mutation EGFR were 30.2% and 35.4% respectively(P =0.524),disease control rates were 71.9% and 81.0%,respectively(P =0.292).The comparison of the RR and DCR of first-line chemotherapy in patients with EGFR mutation and wild lung adenocarcinoma was of no significant difference.The median progression free survival time of EGFR wild type was 4.6 months and that of EGFR mutation was 5.3 months,and there was no significant difference between these two types kinds of patients(P=0.299).Conclusion The impact of EGFR gene mutation to the short-term effect and progression free survival of first-line chemotherapy is not significant.
展开▼
